Daniel Wrapp to Palivizumab
This is a "connection" page, showing publications Daniel Wrapp has written about Palivizumab.
Connection Strength
0.170
-
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017 05 03; 9(388).
Score: 0.170
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.